LYOPHILIZED VIRUS FORMULATIONS

Abstract

The present invention relates to a liquid composition characterized in that it comprises: a live attenuated herpes simplex virus 1 (HSV-1); 17.5 mg / mL to 22.5 mg / mL of recombinant human serum albumin (rHSA); less than 5 mg / mL of sucrose; 26 mg / mL to 32 mg / mL of sorbitol; 13.5 mg / mL to 16 mg / mL of potassium phosphate and 3 mg / mL to 7 mg / mL of sodium chloride, wherein the liquid composition comprises no more than 0.01 mM of any of lactose, gelatin, antibiotic and free amino acids.

Description

LYOPHILIZED VIRUS FORMULATIONS CROSS REFERENCE TO RELATED APPLICATIONS This application claims priority over Provisional Application No. 262 / 785,307, filed on December 27, 2018, the full content of which is incorporated herein by reference. BACKGROUND Live viruses, such as the herpes simplex virus, are typically unstable for extended periods at storage temperatures above -80°C. This lack of thermostability poses a challenge for such viruses, particularly for therapeutic viruses in liquid formulations. These therapeutic virus compositions must be stored and transported frozen and used soon after thawing to maintain their therapeutically effective infectivity. The lack of thermostability poses operational challenges that increase manufacturing, storage, and transportation costs. During manufacturing operations, for example, freeze / thaw cycles can lead to suboptimal process yields and a lack of necessary supply chain flexibility. Storage and transportation also present challenges, resulting in complicated handling and complex supply chains. The lack of thermostability also presents commercial challenges. Similar virus compositions that require storage at -80°C to ensure a stable half-life lead to complex storage and handling protocols for healthcare providers. These limitations increase the risk of product loss (e.g., due to improper handling) and residual product (e.g., the entire product is not used after thawing). This has the potential to increase costs for the customer. Lyophilization is a freeze-drying process that removes water from a drug product, which is then frozen and placed under vacuum. During this process, the water sublimates, changing directly from ice to vapor without passing through the liquid phase. Lyophilization is widely used to improve the stability of pharmaceutical and biopharmaceutical products, including those comprising chemical APIs, peptides, oligonucleotides, and proteins (e.g., collagens, enzymes, and antibodies), ultimately enhancing storage stability and extending half-life. However, this process is not without its challenges. Lyophilization can lead to delayed drug release and the rejection of drug product batches (Roy et al., Troubleshooting During the Manufacture of Lyophilized Drug Product—Begin Prepared for the Unexpected, Am Pharm Rev (2012) available at www.americanpharmaceuticalreview.com / FeaturedArticles / 126958-Troubleshooting-During-the-Manufacture-of-Lyophilized-Drug-Product-Being-. Rea / nn / Lznz / E / Yii Prepared-for-the-Unexpected). In the context of viral formulations, the freeze-drying process can damage the virus, leading to low quantities of active virus after reconstitution (Hansen L, Daoussi R, Vervaet C, Remon JP, De Beer T (2015) Freeze-drying of live virus vaccines: A review. Vaccine 33:5507-5519). The US Food and Drug Administration also notes that some disadvantages of freeze-drying include increased handling and processing times, required for the reconstitution of sterile diluents, and the need for expensive and / or complex equipment. SUMMARY This disclosure provides a formulation or composition of live viruses that can be lyophilized to produce a stable lyophilized virus product that allows for storage at cold and ambient temperatures. The lyophilized product or powder is also provided herein. Without intending to be bound by any specific theory, the formulations, products, and powders disclosed herein reduce limitations during the manufacture, transport, storage, and use of the virus, providing flexibility while mitigating the loss of viral stability and / or infectivity. The compositions in this disclosure also prevent or minimize virus inactivation.The ability to handle, store, and transport a pharmaceutical product or intermediate product without loss of potency (or activity) is of tremendous value because it allows flexibility in the design of the manufacturing process, labeling, packaging operations, distribution of the final product supply chain, and in the handling by healthcare providers. Accordingly, this disclosure provides a liquid composition comprising a live attenuated virus, human serum albumin (e.g., recombinant human serum albumin “rHSA”), a sugar other than lactose, an alditol, a phosphate source, and a chloride source. For illustrative purposes, the liquid composition comprises more than approximately 5 mg / mL and less than approximately 25 mg / mL of rHSA, optionally more than approximately 10 mg / mL and less than approximately 25 mg / mL of rHSA. In various aspects, the liquid composition comprises more than approximately 15 mg / mL and less than approximately 25 mg / mL of rHSA, optionally comprising approximately 17.5 mg / mL to approximately 22.5 mg / mL of rHSA, optionally approximately 20 mg / mL ± 2 mg / mL of rHSA.In various aspects, the sugar in the liquid composition is sucrose, and optionally the liquid composition comprises less than approximately 15 mg / mL of sucrose, less than approximately 10 mg / mL of sucrose, or less than approximately 5 mg / mL of sucrose. In various aspects, the liquid composition comprises less than approximately 3.8 mg / mL ± 0.38 mg / mL of sucrose. In various cases, the alditol in the liquid composition is sorbitol, and optionally the liquid composition comprises more than approximately 10 mg / mL of sorbitol and less than approximately 50 mg / mL of sorbitol, or optionally, more than approximately 20 mg / mL of sorbitol and less than approximately 40 mg / mL of sorbitol. In some aspects, the liquid composition comprises less than approximately 45 mg / mL of sorbitol, less than approximately 40 mg / mL of sorbitol, less than approximately 35 mg / mL of sorbitol, or approximately 26 mg to approximately 32 mg / mL of sorbitol.In some aspects, the phosphate source present in the liquid composition is potassium phosphate. In various cases, the liquid composition comprises more than approximately 5 mg / mL and less than approximately 45 mg / mL of potassium phosphate, optionally less than approximately 40 mg / mL of potassium phosphate (e.g., less than approximately 30 mg / mL of potassium phosphate, less than approximately 20 mg / mL of potassium phosphate), or approximately 13.5 mg to approximately 16 mg / mL of potassium phosphate. In some cases, the chloride source of the liquid composition is sodium chloride, and optionally, it is present in an amount greater than approximately 1 mg / mL and less than approximately 20 mg / mL of sodium chloride. In some aspects, the liquid composition comprises less than approximately 15 mg / mL of sodium chloride or less than approximately 10 mg / mL of sodium chloride, for example, approximately 3 mg to approximately 7 mg / mL of sodium chloride.In illustrative cases, the composition is substantially free of lactose, gelatin, antibiotics, and amino acids. In various aspects, the liquid composition essentially consists of: live attenuated virus, rHSA, sucrose, sorbitol, potassium phosphate, and sodium chloride. The liquid composition in some aspects has a pH of approximately 7.2 to approximately 7.6, optionally, a pH of approximately 7.4. In various aspects, the liquid composition has an osmolality of less than approximately 700 mOsm / kg, optionally, less than approximately 650 mOsm / kg (e.g., an osmolality of less than approximately 600 mOsm / kg, optionally, approximately 525 mOsm / kg to approximately 575 mOsm / kg). In certain aspects, the liquid composition comprises no more than approximately 0.01 mM of any of lactose, gelatin, antibiotic, and free amino acids, optionally no more than approximately 0.0.01 mM of any of lactose, gelatin, antibiotic, and free amino acids. In some embodiments, the live attenuated virus is a herpes simplex virus (HSV), optionally a strain of herpes simplex virus 1 (HSV-1). In several embodiments, the HSV-1 strain is selected from the group consisting of the JS1 strain, the 17+ strain, the F strain, and the KOS strain. In one specific embodiment, the HSV-1 is talimogene laherparepvec. In several embodiments, when the liquid composition is lyophilized and reconstituted with water to produce a reconstituted product, the potency of the live attenuated virus in the reconstituted product is at least or approximately 30% of the potency of the live attenuated virus before the liquid composition is lyophilized, optionally at least or approximately 35% of the potency of the live attenuated virus before the liquid composition is lyophilized.In some respects, the liquid composition is lyophilized, then reconstituted with water to produce a reconstituted product; the potency of the live attenuated virus in the reconstituted product is at least or approximately 30% of the potency of the live attenuated virus before the liquid composition is lyophilized, optionally at least or approximately 40% of the potency of the live attenuated virus before the liquid composition is lyophilized. Also provided herein is a liquid composition comprising a live attenuated HSV-1 (e.g., talimogene laherparepvec), approximately 18 mg / mL to approximately 22 mg / mL of human serum albumin (e.g., rHSA), approximately 3.4 mg / mL to approximately 4.2 mg / mL of sucrose, approximately 26 mg / mL to approximately 31.9 mg / mL of sorbitol, approximately 13 mg / mL to approximately 16 mg / mL of potassium phosphate, and approximately 5.1 mg / mL to approximately 6.3 mg / mL of sodium chloride. A liquid composition is further provided comprising a live attenuated HSV-1 (e.g., talimogene laherparepvec), approximately 1.0% to approximately 3.0% (w / v) of human serum albumin (e.g., rHSA), approximately 0.25% to approximately 0.45% (w / v) of sucrose, approximately 2.0 to approximately 4% (w / v) of sorbitol, approximately 60 mM to approximately 100 mM of potassium phosphate, and approximately 80 to approximately 110 mM of sodium chloride. This document also provides a product produced by any of the currently disclosed lyophilization or cryodesiccation methods. This disclosure provides a powder produced by a method comprising removing water (e.g., by lyophilization) from a composition comprising a live attenuated virus (e.g., HSV-1, optionally talimogene laherparepvec), recombinant human serum albumin (rHSA), a sugar other than lactose, an alditol, a phosphate source, and a chloride source, wherein the composition is substantially free of lactose, gelatin, antibiotics, and free amino acids. Optionally, the composition from which water is removed (e.g., by lyophilization) comprises a live attenuated HSV-1 (e.g., talimogene laherparepvec), approximately 18 mg / mL to approximately 22 mg / mL of human serum albumin (e.g., rHSA), approximately 3.4 mg / mL to approximately 4.2 mg / mL of sucrose, and approximately 26 mg / mL to approximately 31 mg / mL of lactose.9 mg / mL of sorbitol, approximately 13 mg / mL to approximately 16 mg / mL of potassium phosphate, and approximately 5.1 mg / mL to approximately 6.3 mg / mL of sodium chloride. A powder produced by a method comprising removing water (e.g., by lyophilization) from a composition comprising a live attenuated HSV-1 (e.g., talimogene laherparepvec), approximately 1.0% to approximately 3.0% (w / v) of human serum albumin (e.g., rHSA), approximately 0.25% to approximately 0.45% (w / v) of sucrose, approximately 2.0% to approximately 4% (w / v) of sorbitol, approximately 60 mM to approximately 100 mM of potassium phosphate, and approximately 80 to approximately 110 mM of sodium chloride is also provided. Also provided herein is a powder produced by a method comprising removing water from a composition comprising live attenuated HSV-1, approximately 18 mg / mL to approximately 22 mg / mL of recombinant human serum albumin (rHSA), approximately 3.4 mg / mL to approximately 4.2 mg / mL of sucrose, approximately 26 mg / mL to 31.9 mg / mL of sorbitol, approximately 13 mg / mL to approximately 16 mg / mL of potassium phosphate, and approximately 5.1 mg / mL to approximately 6.3 mg / mL of sodium chloride. In some aspects, the composition is frozen to obtain a composition comprising ice before water removal, and optionally, the method further comprises placing the composition under vacuum to remove water (e.g., by lyophilization).In certain respects, the powder is stable in storage for at least or approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 months at a temperature below or approximately 8°C. A liquid composition comprising water and the currently disclosed product or the currently disclosed dry powder is provided herein. In some aspects, the liquid composition comprises approximately 0.95 mL to approximately 1.5 mL of water, optionally approximately 1.0 mL of water. In certain aspects, the liquid composition comprises at least or approximately 1 x 10⁶ PFU of live attenuated virus (e.g., talimogene laherparepvec) per mL of liquid composition and / or has a pH of approximately 7.4. In other aspects, the liquid composition comprises at least or approximately 1 x 10⁸ PFU of live attenuated virus (e.g., talimogene laherparepvec) per mL of liquid composition and / or has a pH of approximately 7.4. A powder comprising a live attenuated virus is further provided by this disclosure. In illustrative embodiments, the powder further comprises human serum albumin (e.g., rHSA), a sugar other than lactose, a sugar alcohol, a phosphate source, and a chloride source, wherein the composition is substantially free of lactose, gelatin, antibiotics, and free amino acids. Optionally, the powder comprises approximately 24.66% to approximately 30.14% by weight of rHSA. In illustrative cases, the sugar is sucrose and is optionally present in an amount of approximately 2.5% to approximately 7.5% by weight, or optionally, approximately 4.68% to approximately 5.72% by weight. In certain cases, the alditol present in the powder is sorbitol and is optionally present in an amount of approximately 25% to approximately 33% by weight, or approximately 35.76% by weight. Rea / nn / Lznz / E / Yii by weight to approximately 43.7% by weight. In certain aspects, the potassium source is potassium phosphate and the powder comprises approximately 15% to approximately 25% by weight of potassium phosphate, optionally, approximately 17.87% to approximately 21.85% by weight. In various aspects, the chloride source is sodium chloride and the powder comprises approximately 5% to approximately 10% by weight of sodium chloride, optionally, approximately 7.0% to approximately 8.6% by weight of sodium chloride. In illustrative cases, the powder, after the addition of approximately 1 mL of water, produces a liquid composition comprising approximately 80 mM to approximately 85 mM of potassium phosphate, approximately 95 mM to approximately 100 mM of sodium chloride, approximately 2.8% (w / v) to approximately 3.0% (w / v) of sorbitol, approximately 0.36% (w / v) to approximately 0.40% (w / v) of sucrose, and from approximately 1.98% (w / v) to approximately 2.02% (w / v) of recombinant HSA. This disclosure also provides methods for preparing an oncolytic virus for administration to a human subject, comprising adding water to any one of the currently disclosed powders, optionally wherein approximately 1.0 mL to approximately 1.2 mL of water is added to the powder. A method for treating melanoma in a human subject is further provided, comprising adding water to any one of the currently disclosed powders, optionally wherein approximately 1.0 mL to approximately 1.2 mL of water is added to the powder to obtain a liquid composition, and injecting the liquid composition into the human subject. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is a cumulative counts / mL chart representing the amount of subvisible particles > 10 pm in reconstituted material formulated to contain 1x108PFU / mL. Figure 2 is a cumulative counts / mL chart representing the amount of subvisible particles >25 pm in reconstituted material formulated to contain 1 x108UFP / mL. Figure 3 compares the degradation rates of formulations F1, F2, and F3 (each containing talimogene laherparepvec) to F4 (also containing talimogene laherparepvec) when stored as a liquid at 5°C (left half of Figure 3) and 25°C (right half of Figure 3) for 6 weeks. Values ​​greater than 1 indicate improved degradation rates relative to F4 (worse stability), and values ​​less than 1 indicate the degree of improved degradation rate (better stability) relative to F4. Figure 4 compares the degradation rates of freeze-dried formulations of F1, F2, and F3 stored at 5°C for 10 weeks, relative to F4. Values ​​greater than 1 indicate a coefficient of increase in the degradation rate relative to F4 (i.e., worse stability), and values ​​less than 1 (not present) would have Rea / nn / Lznz / E / Yii indicated the coefficient of decrease in the rate of degradation (i.e., better stability) relative to F4. Figure 5 shows the activity recovery after freeze-drying of F1, F2, and F3 relative to formulation F4. The amount of activity recovered after freeze-drying was calculated for each formulation by dividing the amount of activity initially present after freeze-drying by the amount of activity present in the liquid formulation (pre-freeze-drying) and then normalizing to the fraction of activity recovered in formulation F4. Values ​​greater than 0% (not present) indicate a higher (i.e., better) proportion of recovered activity compared to the amount of activity recovered with formulation F4. Values ​​less than 0% indicate a lower (i.e., worse) proportion of recovered activity compared to the amount of activity recovered with formulation F4. DETAILED DESCRIPTION This document provides compositions of live viruses suitable for lyophilization or cryodesiccation. Related powders and freeze-dried or lyophilized products are also provided. These powders and products are advantageously labeled for stable storage and extended shelf life, characterized by minimal or reduced loss of potency of the live virus after lyophilization or cryodesiccation. Furthermore, the liquid compositions described herein adequately stabilize a live attenuated virus in both the lyophilized and liquid states. This disclosure provides a liquid composition comprising a live attenuated virus, human serum albumin (e.g., rHSA), a sugar other than lactose, an alditol, a phosphate source, and a chloride source. In various aspects, the liquid composition comprises the live attenuated virus, HSA (e.g., rHSA), sucrose, sorbitol, potassium phosphate, and sodium chloride. For illustrative purposes, the liquid composition comprises approximately 18 mg / mL to approximately 22 mg / mL of HSA (e.g., rHSA) or approximately 1.0% to approximately 3.0% (w / v) of HSA (e.g., rHSA). In various cases, the liquid composition comprises approximately 3.4 mg / mL to approximately 4.2 mg / mL of sucrose or approximately 0.25% to approximately 0.45% (w / v) of sucrose. In some aspects, the composition comprises approximately 26 mg / mL to approximately 31.9 mg / mL of sorbitol or approximately 2.0% to approximately 4.0% (w / v) of sorbitol.In various aspects, the liquid composition comprises approximately 13 mg / mL to approximately 16 mg / mL of potassium phosphate or approximately 60 mM to approximately 100 mM of potassium phosphate. In certain aspects, the liquid composition comprises approximately 5.1 mg / mL to approximately 6.3 mg / mL of sodium chloride, or approximately 80 to approximately 110 mM of sodium chloride. Accordingly, a liquid composition comprising a live attenuated HSV-1 (e.g., talimogene laherparepvec) is provided herein. Rea / nn / Lznz / E / Yii approximately 18 mg / mL to approximately 22 mg / mL of HSA (e.g., rHSA), approximately 3.4 mg / mL to approximately 4.2 mg / mL of sucrose, approximately 26 mg / mL to approximately 31.9 mg / mL of sorbitol, approximately 13 mg / mL to approximately 16 mg / mL of potassium phosphate, and approximately 5.1 mg / mL to approximately 6.3 mg / mL of sodium chloride. A liquid composition is further provided comprising a live attenuated HSV-1 (e.g., talimogene laherparepvec), approximately 1.0% to approximately 3.0% (w / v) of HSA (e.g., rHSA), approximately 0.25% to approximately 0.45% (w / v) of sucrose, approximately 2.0% to approximately 4% (w / v) of sorbitol, approximately 60 mM to approximately 100 mM of potassium phosphate, and approximately 80 to approximately 110 mM of sodium chloride.As used herein, the term “approximately” refers to a 5% variation between the stated values, or in the case of a range of values, means a 5% variation between the lower and upper limits of such ranges. The liquid compositions in this disclosure are, in the illustrative embodiments, aqueous solutions, sterilized, for example, filter-sterilized, and / or substantially free of bacteria and endotoxins. Human serum albumin (HSA) In various respects, the liquid composition comprises an albumin, optionally human serum albumin (HSA). HSA is the most abundant protein found in human blood plasma. In various respects, the liquid composition comprises recombinant HSA. As used herein, the term “recombinant” in the context of “HSA” means that the HSA is a product designed by genetic engineering or prepared by recombinant production methods. A recombinant HSA is not derived from (isolated or purified from) a natural product (e.g., human plasma). Rather, genetically engineered cells may be used to produce the HSA. In various cases, the liquid composition comprises rHSA, and, optionally, the HSA is produced using yeast-based expression.In various aspects, the currently disclosed liquid composition comprises less than approximately 50 mg / mL, less than approximately 45 mg / mL, less than approximately 40 mg / mL, less than approximately 35 mg / mL, or less than approximately 30 mg / mL of HSA (e.g., rSHA). In various aspects, the currently disclosed liquid composition comprises more than approximately 1 mg / mL, more than approximately 2 mg / mL, more than approximately 3 mg / mL, more than approximately 4 mg / mL, more than approximately 5 mg / mL, more than approximately 10 mg / mL, more than approximately 15 mg / mL, or more than approximately 20 mg / mL of HSA (e.g., rHSA). Optionally, the liquid composition comprises more than approximately 5 mg / mL and less than approximately 25 mg / mL of HSA (e.g., rHSA), or optionally, more than approximately 10 mg / mL and less than approximately 25 mg / mL. Rea / nn / Lznz / E / Yii mg / mL of HSA (e.g., rHSA) or more than approximately 15 mg / mL and less than approximately 25 mg / mL of HSA (e.g., rHSA). In various cases, the liquid composition comprises approximately 17.5 mg / mL to approximately 22.5 mg / mL of HSA (e.g., rHSA), for example, approximately 20 mg / mL ± 2 mg / mL of HSA (e.g., rHSA), optionally approximately 20 mg / mL ± 1 mg / mL of HSA (e.g., rHSA). In one embodiment, the liquid composition comprises approximately 20 mg / mL of HSA (e.g., rHSA). In several aspects, the currently disclosed liquid composition comprises less than approximately 20% (w / v) (e.g., less than approximately 15% (w / v), less than approximately 10% (w / v), less than approximately 5% (w / v) of HSA (e.g., rHSA). In some aspects, the currently disclosed liquid composition comprises less than 3% (w / v) and more than 0.1% (w / v), optionally approximately 1.8% (w / v) to approximately 2.2% (w / v) of HSA (e.g., rHSA). In some aspects, the currently disclosed liquid composition comprises approximately 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, or 2.5% (w / v) of HSA (e.g., rHSA). In some aspects, the currently disclosed liquid composition comprises approximately 2.0% (w / v) of HSA (e.g., rHSA). In some aspects, the liquid composition comprises less than approximately 5 mM of HSA (e.g., rHSA) and more than approximately 0.001 mM of HSA (e.g., rHSA), for example, approximately 0.001 mM to approximately 4 mM, approximately 0.001 mM to approximately 3 mM, approximately 0.001 mM to approximately 2 mM, approximately 0.001 mM to approximately 1 mM, or approximately 0.001 mM to approximately 0.5 mM. In various aspects, HSA (e.g., rHSA) is present in the liquid composition in an amount of approximately 0.0.01 mM to approximately 1 mM or approximately 0.05 mM to approximately 0.5 mM, optionally, approximately 0.3 mM of HSA (e.g., rHSA). Sugars In various aspects, the liquid composition includes a sugar, and this sugar is different from lactose. Advantageously, the composition and its related products described herein are suitable for administration to individuals with a lactose allergy or lactose intolerance. In some cases, the sugar is dextrose, fructose, galactose, glucose, raffinose, trehalose, or sucrose. In various aspects, the sugar in the liquid composition is sucrose. In various aspects, the sugar (e.g., sucrose) is present in the liquid composition in an amount of less than approximately 50 mg / mL, less than approximately 45 mg / mL, less than approximately 40 mg / mL, less than approximately 35 mg / mL, less than approximately 30 mg / mL, less than approximately 25 mg / mL, or less than approximately 20 mg / mL.In some aspects, the liquid composition comprises less than approximately 15 mg / mL of sugar (e.g., sucrose), less than approximately 10 mg / mL of sugar (e.g., sucrose), or less than approximately 5 mg / mL of sugar (e.g., sucrose). In various aspects, the currently disclosed liquid composition comprises more than approximately 1 mg / mL, more than approximately 2 mg / mL, or more than approximately 3 mg / mL of sugar (e.g., sucrose); optionally, the liquid composition comprises from approximately 2 mg / mL to approximately 5 mg / mL. In some aspects, the liquid composition comprises less than approximately 3.8 mg / mL ± 0.38 mg / mL of sucrose. In other aspects, the liquid composition comprises approximately 3.8 mg / mL of sucrose.In various aspects, the currently disclosed liquid composition comprises less than approximately 10% (w / v) (e.g., less than approximately 9% (w / v), less than approximately 8% (w / v), less than approximately 7% (w / v), less than approximately 6% (w / v), less than approximately 5% (w / v), less than approximately 4% (w / v), less than approximately 3% (w / v), less than approximately 2% (w / v), less than approximately 1% (w / v)) of sugar (e.g., sucrose). In some aspects, the currently disclosed liquid composition comprises less than 0.5% (w / v) and more than 0.1% (w / v), optionally approximately 0.30% (w / v) to approximately 0.42% (w / v) of sugar (e.g., sucrose). In some aspects, the currently disclosed liquid composition comprises approximately 0.38% (w / v) of sugar (e.g., sucrose).In some aspects, the liquid composition comprises less than approximately 50 mM of sugar (e.g., sucrose) and more than approximately 1 mM of sugar (e.g., sucrose), for example, approximately 1 mM to approximately 40 mM, approximately 1 mM to approximately 30 mM, approximately 1 mM to approximately 20 mM, approximately 1 mM to approximately 15 mM, approximately 5 mM to approximately 40 mM, approximately 5 mM to approximately 30 mM, approximately 5 mM to approximately 20 mM, approximately 5 mM to approximately 15 mM. In various aspects, sugar (e.g., sucrose) is present in the liquid composition in an amount of approximately 5 mM to approximately 15 mM or approximately 10 mM to approximately 15 mM, optionally approximately 11 mM of sugar (e.g., sucrose). Alditoles In various aspects, the liquid composition comprises an alditol, for example, mannitol, sorbitol, xylitol, maltitol, maltitol syrup, lactitol, erythritol, isomalt, and hydrogenated starch hydrolysate. In various cases, the alditol in the liquid composition is sorbitol. In certain aspects, the liquid composition comprises more than approximately 5 mg / mL of alditol (for example, sorbitol) and less than approximately 50 mg / mL of alditol (for example, sorbitol). In certain aspects, the liquid composition comprises more than approximately 15 mg / mL, more than approximately 20 mg / mL, or more than approximately 25 mg / mL of alditol. Rea / nn / Lznz / E / Yii (e.g., sorbitol). In some aspects, the liquid composition comprises less than approximately 45 mg / mL of alditol (e.g., sorbitol), less than approximately 40 mg / mL of alditol (e.g., sorbitol), or less than approximately 35 mg / mL of alditol (e.g., sorbitol). In various cases, the liquid composition comprises approximately 26 mg / mL to approximately 32 mg / mL of alditol (e.g., sorbitol). In certain cases, the liquid composition comprises approximately 29 mg / mL of alditol (e.g., sorbitol). In various respects, the currently disclosed liquid composition comprises less than approximately 10% (w / v) (e.g., less than approximately 9% (w / v), less than approximately 8% (w / v), less than approximately 7% (w / v), less than approximately 6% (w / v), less than approximately 5% (w / v), less than approximately 4% (w / v), or less than approximately 3% (w / v) of alditol (e.g., sorbitol).In some aspects, the currently disclosed liquid composition comprises less than 3.5% (w / v) and more than 2.5% (w / v), optionally approximately 2.6% (w / v) to approximately 3.2% (w / v) of alditol (e.g., sorbitol). In some aspects, the currently disclosed liquid composition comprises approximately 2.9% (w / v) of alditol (e.g., sorbitol). In some aspects, the liquid composition comprises less than approximately 500 mM of alditol (e.g., sorbitol) and more than approximately 50 mM of sugar (e.g., sorbitol), e.g., approximately 50 mM to approximately 400 mM, approximately 50 mM to approximately 300 mM, approximately 50 mM to approximately 200 mM, approximately 75 mM to approximately 200 mM, approximately 100 mM to approximately 200 mM, approximately 125 mM to approximately 175 mM, approximately 150 mM to approximately 170 mM.In various respects, alditol (e.g., sorbitol) is present in the liquid composition in an amount of approximately 140 mM to approximately 175 mM or approximately 150 mM to approximately 167 mM, optionally, approximately 159 mM of alditol (e.g., sorbitol). Phosphate sources In several respects, the liquid composition of this disclosure comprises a phosphate source.The source may be one of the following: Aluminum phosphate, bone phosphate, calcium phosphate, calcium orthophosphate, anhydrous dibasic calcium phosphate, bone calcium phosphate ash, dibasic calcium phosphate dihydrate, anhydrous dibasic calcium phosphate, dibasic calcium phosphate dihydrate, tribasic calcium phosphate, tribasic calcium phosphate, dibasic calcium phosphate dihydrate, di-calcium phosphate, dicalcium phosphate, dicalcium phosphates, neutral calcium phosphate, calcium orthophosphate, aluminum phosphate, calcium phosphate, magnesium phosphate, neutral calcium phosphate, Os phosphate, tricalcium phosphate, precipitated calcium phosphate, calcium phosphate precipitate, precipitate of Calcium phosphate, Tertiary calcium phosphate, Tricalcium phosphate, Whitlockite, Magnesium phosphate, Merisier, Potassium phosphate, Dibasic potassium phosphate, Dipotassium hydrogen orthophosphate, Dipotassium monophosphate. Rea / nn / Lznz / E / Yii Dipotassium phosphate, Monobasic potassium phosphate, Acid potassium phosphate, Potassium bisphosphate, Potassium dihydrogen orthophosphate, Potassium hydrogen phosphate, Dipotassium phosphate, Potassium hydrogen phosphate, Potassium phosphate, Dibasic potassium phosphate, Monobasic potassium phosphate, Sodium phosphate, Anhydrous sodium phosphate, Dibasic sodium phosphate, Disodium hydrogen orthophosphate, Sodium hydrogen orthophosphate dodecahydrate, Disodium hydrogen phosphate, Disodium phosphate, Sodium phosphate, Phosphate salts, Phosphate salts, Sodium orthophosphate, Disodium hydrogen orthophosphate, Disodium hydrogen phosphate, Sodium orthophosphate, Anhydrous sodium phosphate, Dibasic sodium phosphate, and Phosphorus. In some aspects, the phosphate source present in the liquid composition is sodium phosphate or potassium phosphate. In some specific aspects, the phosphate source present in the liquid composition is potassium phosphate.In various cases, the liquid composition comprises more than approximately 5 mg / mL and less than approximately 45 mg / mL of the phosphate source (e.g., potassium phosphate), optionally less than approximately 40 mg / mL of the phosphate source (e.g., potassium phosphate), less than approximately 30 mg / mL of the phosphate source (e.g., potassium phosphate), less than approximately 20 mg / mL of the phosphate source (e.g., potassium phosphate), or approximately 13.5 mg to approximately 16 mg / mL of phosphate from the phosphate source (e.g., potassium phosphate). In one particular embodiment, the liquid composition comprises approximately 14.5 mg / mL of phosphate (e.g., potassium phosphate).In various cases, the liquid composition comprises more than approximately 25 mM and less than approximately 500 mM of the phosphate source (e.g., potassium phosphate), e.g., approximately 25 mM to approximately 400 mM, approximately 25 mM to approximately 300 mM, approximately 25 mM to approximately 200 mM, approximately 25 mM to approximately 100 mM, approximately 50 mM to approximately 150 mM, approximately 50 mM to approximately 100 mM.Optionally, less than approximately 100 mM of the phosphate source (e.g., potassium phosphate), for example, less than approximately 90 mM of the phosphate source (e.g., potassium phosphate), more than approximately 50 mM and less than approximately 90 mM, approximately 60 mM to approximately 90 mM, approximately 70 mM to approximately 90 mM, approximately 80 mM to approximately 85 mM of the phosphate source (e.g., potassium phosphate), or approximately 75 mM to approximately 92 mM of the phosphate source (e.g., potassium phosphate). In one particular embodiment, the liquid composition comprises approximately 83 mM of the phosphate source (e.g., potassium phosphate). Sources of chloride In various aspects, the liquid composition of this disclosure comprises a chloride source (e.g., sodium or potassium chloride). In some cases, the chloride source is sodium chloride. For illustrative purposes, the chloride source (e.g., NaCl) is present in an amount greater than approximately 1 mg / mL and less than approximately 20 mg / mL of the chloride source (e.g., NaCl) (e.g., approximately 1 mg / mL to approximately 15 mg / mL, approximately 1 mg / mL to approximately 10 mg / mL, approximately 1 mg / mL to approximately 7.5 mg / mL, approximately 3 mg / mL to approximately 15 mg / mL, approximately 3 mg / mL to approximately 10 mg / mL, approximately 3 mg / mL to approximately 7.5 mg / mL).In some aspects, the liquid composition comprises less than approximately 15 mg / mL of the chloride source (e.g., NaCl) or less than approximately 10 mg / mL of the chloride source (e.g., NaCl), e.g., approximately 3 mg to approximately 7 mg / mL of the chloride source (e.g., NaCl), optionally, approximately 5.7 mg / mL. In various cases, the liquid composition comprises more than approximately 25 mM and less than approximately 500 mM of the chloride source (e.g., NaCl), e.g., approximately 25 mM to approximately 400 mM, approximately 25 mM to approximately 300 mM, approximately 25 mM to approximately 200 mM, approximately 25 mM to approximately 150 mM, approximately 50 mM to approximately 150 mM, approximately 75 mM to approximately 125 mM. Optionally, less than approximately 150 mM of the chloride source (e.g., NaCl), for example, less than approximately 125 mM of the chloride source (e.g., NaCl), more than approximately 50 mM and less than approximately 125 mM, approximately 60 mM to approximately 120 mM, approximately 70 mM to approximately 110 mM, approximately 80 mM to approximately 110 mM of the chloride source (e.g., NaCl), or approximately 88 mM to approximately 108 mM of the chloride source (e.g., NaCl), optionally, approximately 98 mM. Lactose, Gelatin, Antibiotic, and Free Amino Acids For illustrative purposes, the liquid composition is substantially free of added lactose. For illustrative purposes, the liquid composition is substantially free of added gelatin. For illustrative purposes, the liquid composition is substantially free of added antibiotics (e.g., neomycin, kanamycin, gentamicin, ampicillin, carbenicillin, cefotaxime, fosmidocin, actinomycin, polymyxin, penicillin, streptomycin). For illustrative purposes, the liquid composition is substantially free of added free amino acids. For example, the liquid composition is prepared with no lactose, no gelatin, no antibiotics, and no free amino acids. In certain respects, none of these components (no lactose, gelatin, antibiotics, or free amino acids) were added when the currently disclosed liquid composition, powder, or freeze-dried product was prepared. βρο / ηη / ίζηζ / Β / γυ As used herein, the term “free amino acids” refers to added unbound or unlinked amino acids or to amino acids that are not linked by a peptide bond to another amino acid. In various instances, the liquid composition is substantially free of any “free amino acids,” meaning that free amino acids were not added to the liquid composition as a component. Free amino acids do not refer to any unbound or unlinked amino acids present in the composition due to, for example, HSA degradation (e.g., rHSA). For illustrative purposes, the liquid composition is substantially free of Glu or His. As used herein, “substantially exempt” means less than 0.01% by weight or less than 0.01% (w / v) or less than 100 ppm. In certain aspects, the liquid composition comprises not more than approximately 0.01 mM of any of lactose, gelatin, antibiotic, and free amino acids, and optionally, not more than approximately 0.001 mM of any of lactose, gelatin, antibiotic, and free amino acids. pH and Osmolality In various aspects, the liquid composition (e.g., reconstituted lyophilized composition) has a pH of approximately 7.0 to approximately 7.8, optionally approximately 7.2 to approximately 7.6 (e.g., 7.2, 7.3, 7.4, 7.5, 7.6). In various cases, the pH of the liquid composition is approximately 7.4 ± 0.05. In various aspects, the liquid composition has an osmolality of less than approximately 700 mOsm / kg, optionally less than approximately 650 mOsm / kg (for example, an osmolality of less than approximately 600 mOsm / kg, optionally from approximately 525 mOsm / kg to approximately 575 mOsm / kg). For illustrative purposes, the osmolality of the liquid composition is approximately 540 mOsm / kg to approximately 560 mOsm / kg, or approximately 550 mOsm / kg. Traditional frozen formulations can have osmolalities in the range of 700-900 mOsm / kg. The lyophilized formulations of the present invention, however, demonstrate the desired properties (enhanced potency after lyophilization and extended shelf life at temperatures suitable for a supply chain) with an osmolality (e.g., after reconstitution) lower than that of such traditional frozen formulations. The lower osmolality of the reconstituted lyophilized formulations is not expected to alter the local tolerability of the lyophilized drug product after administration or its local biological effect, and may improve local tolerability with respect to, for example, discomfort, irritation, a burning sensation, or pain after injection. Live viruses The herpesvirus particle is a complex structure of a double-stranded DNA genome packaged in an icosahedral protein capsid that is enveloped in a cell-derived membrane bilayer. Sandwiched between the capsid and the lipid envelope is a layer of viral proteins known as the tegument [Roizman B (1982) The Family Herpesviridae: General Description, taxonomy and classification. The Viruses, Vol A, Herpesviruses. New York: Plenum Press, Mettenleiter TC (2002) Herpesvirus assembly and egress. Journal of virology 76:1537-1547.]. The presence of a membrane envelope is a distinguishing feature of many different types of animal viruses.In the formulation of compositions to stabilize live viruses, the lipid envelope appears to confer significant physical instability to the viral particle, making it difficult to stabilize this class of viruses, especially when compared to non-enveloped mammalian viruses such as adenovirus, reovirus, and poliovirus. For example, when stored at 2–8°C, Adenovirus Type 5 has been shown to be stable for 2 years, and poliovirus and reovirus for at least 1 year [Sokhey et al., (1988). Vaccine 6: 12–13; Berard and Coombs (2009). Current protocols in microbiology: 15°C–1; and Evans RK, et al. (2004) J Pharm Sci 93: 2458–2475]. Poxvirus appears to be the only enveloped animal virus that exhibits similar storage stability durations at similar temperatures. However, the poxvirus is structurally distinct from other enveloped animal viruses because it contains a double envelope and other structural differences [Condit et al., (2006).Advances in virus research 66: 31-124, Moss B (1987) The molecular biology of poxviruses. The Molecular Basis of Viral Replication. Springer. pp. 499-516]. In turn, poxviruses are remarkably stable as demonstrated by prolonged storage observed in archived tissues, environmental samples, and in laboratory storage of dried samples at 2-8°C for approximately 60 years [McCollum et al., (2014) Poxvirus viability and signatures in historical records. Emerging infectious diseases 20: 177; FDA found more than smallpox viruses in storage room (nd). Available at: https: / / www.washingtonpost.com / national / health-science / fda-foundmore-than-smallpox-vials-in-storage-room / 2014 / 07 / 16 / 850d4b12-0d22-11 e4-8341 b8072b1e7348_story.html. Accessed November 7, 2015; CDC Media Statement on Newly Discovered Smallpox Specimens (n.d.). Available at: http: / / www.cdc.gov / media / releases / 2014 / s0708-NIH.html.Accessed November 7, 2015; Rheinbaben et al., (2007) Environmental resistance, disinfection, and sterilization of poxviruses. Poxvirus. Springer. p. 397-405; and Essbauer et al., (2007) Long-Lasting Stability of Vaccinia Virus (Orthopoxvirus) in Food and Environmental Samples. Zoonoses and public health 54: 118-124],. Oncolytic viruses have demonstrated anticancer activity in a variety of tumor types. Oncolytic immunotherapy is a treatment modality that uses replicating oncolytic viruses that selectively infect and damage cancerous tissues without harming normal tissues. Ongoing studies use a variety of genetically modified viruses, including herpes simplex virus (HSV), vaccinia virus, and reovirus. Rea / nn / Lznz / E / Yii In terms of aspects, the oncolytic virus is derived from a strain of herpes simplex virus 1 (HSV-1) or herpes simplex virus 2 (HSV-2), or a derivative of these, preferably HSV-1. Derivatives include intertype recombinants containing DNA from both HSV-1 and HSV-2 strains. Such intertype recombinants are described in the technique, for example, in Thompson et al., (1998) Virus Genes 1(3); 275-286 and Meignier et al., (1998) J. Infect. Dis. 159; 602-614. Herpes simplex virus strains can be derived from clinical isolates. These strains are isolated from infected individuals, such as those with recurrent oral herpes. Clinical isolates can be examined to determine whether they possess a desired capability or characteristic, such as enhanced replication in tumor cells and / or other cells in vitro and / or in vivo compared to standard laboratory strains, as described in U.S. Patents 7,063,835 and 7,223,593, each of which is incorporated herein by reference. In one embodiment, the herpes simplex virus is a clinical isolate from recurrent oral herpes. Furthermore, viral strains of herpes simplex virus 1 include, but are not limited to, strain JS1, strain 17+, strain F, strain KOS, and strain Patton. Examples of HSV genes that can be modified include virulence genes that encode proteins such as ICP34.5 (y34.5). ICP34.5 acts as a virulence factor during HSV infection, limiting replication in non-dividing cells and rendering the virus non-pathogenic. Another HSV gene that can be modified is the gene that encodes ICP47. ICP47 negatively regulates the expression of major histocompatibility complex (MHC) class I on the surface of infected host cells and the binding of MHC class I to the transporter-associated antigen (TAP). These actions block the transport of antigenic peptides into the endoplasmic reticulum and the loading of MHC class I molecules.Another HSV gene that can be modified is ICP6, the large ribonucleotide reductase subunit, involved in viral DNA synthesis and nucleotide metabolism in non-dividing cells, but not in dividing cells. Thymidine kinase, responsible for the phosphorylation of acyclovir to acyclovir monophosphate, the virion transactivator protein vmw65, glycoprotein H, vhs, ICP43, and the immediate early genes encoding ICP4, ICP27, ICP22, and / or ICP0 can also be modified (in addition to, or alternatively with, the genes mentioned above). The strains of the herpes virus and the methods for producing those strains are also described in U.S. patents numbers 5,824,318; 6,764,675; 6,770,274; 7,063,835; 7,223,593; 7,749,745; 7,744,899; 8,273,568; 8,420,071; and 8,470,577; WIPO publications numbers WO199600007; WO199639841; WO199907394; WO200054795; WO2006002394; and WO201306795; Chinese patent numbers CN128303, CN10230334 and CN 10230335; Varghese and Rabkin, (2002) Cancer Gene Therapy 9:967-97, and βρα / ηη / ίζηζ / Ε / γι Cassady and Ness Parker, (2010) The Open Virology Journal 4:103-108, which are incorporated by reference in their entirety. In one embodiment, the oncolytic virus is talimogene laherparepvec (IMLYGIC®), derived from a clinical strain, the HSV-1 strain JS1, deposited in the European Cell Culture Collection (ECAAC) with registration number 01010209. In talimogene laherparepvec, the HSV-1 viral genes encoding ICP34.5 and ICP47 have been functionally deleted. Functional deletion of ICP47 leads to earlier expression of US11, a gene that promotes viral growth in tumor cells without decreasing tumor selectivity. The coding sequence for human GM-CSF has been inserted into the viral genome at the former ICP34.5 sites (see Liu et al., Gene Ther 10: 292-303, 2003). Other examples of oncolytic viruses include RP1 (HSV-1 / ICP34.57ICP477GMCSF / GALV-GP R(-); RP-2 (HSV-1 / ICP34.57ICP477GM-CSF / GALV-GP R(-) / CTLA-4 binder); and RP3 (HSV-1 / ICP34.5 / ICP477GM-CSF / GALV-GP R(-) / CTLA-4 binder / costimulatory ligands (e.g., CD40L, 4-1BBL, GITRL, OX40L, ICOSL)). In these oncolytic viruses, GALV (gibbon monkey leukemia virus) has been modified with a specific deletion of the R peptide, resulting in GALV-GP R(-). These oncolytic viruses are described in documents WO2017118864, WO2017118865, WO2017118866, WO2017118867, and WO2018127713A1, each of which is incorporated by reference in its entirety. Additional examples of oncolytic viruses include NSC-733972, HF-10, BV-2711, JX-594, Myb34.5, AE-618, Brainwel™, and Heapwel™, Cavatak® (coxsackievirus, CVA21), HF10, Seprehvir®, Reolysin®, enadenotucirev, ONCR-177, and those described in USP documents 10,105,404, WO2018006005, WO2018026872A1, and WO2017181420, each of which is incorporated by reference in its entirety. Additional examples of oncolytic viruses include: [A] G207, an oncolytic HSV-1 derived from the natural HSV-1 strain F having deletions in both copies of the major determinant of HSV neurovirulence, the ICP 34.5 gene, and an inactivating insertion of the E. coli lacZ gene at UL39, which encodes infected cell protein 6 (ICP6), see Mineta et al. (1995) Nat Med 1: 938-943. [B] OrienXOlO, a herpes simplex virus with deletion of both copies of y34.5 and the ICP47 genes, as well as disruption of the ICP6 gene and insertion of the human GM-CSF gene, see Liu et al., (2013) World Journal of Gastroenterology 19 (31): 5138-5143. [C] NV1020, a herpes simplex virus with the junction region of the long (L) and short (S) regions is deleted, including one copy of ICP34.5, UL24 and UL56.34,35. The deleted region was replaced with a fragment of HSV-2 US DNA (US2, US3 (PK), gj and gG), see Todo, et al. (2001) Proc Nati Acad Sel USA. 98: 6396-6401. RrQ / nn / Lznz / E / Yi [D] M032, a herpes simplex virus with deletion of both copies of the ICP34.5 genes and insertion of interleukin 12, see Cassady and Ness Parker, (2010) The Open Virology Journal 4:103-108. [E] VHS2 ImmunoVEX is a herpes simplex virus (HSV-2) with functional deletions of the genes encoding vhs, ICP47, ICP34.5, UL43 and US5. [F] OncoVexGALV / CD, is also derived from the JS1 strain of HSV-1 with the genes encoding ICP34.5 and ICP47 functionally deleted and the gene encoding cytosine deaminase and gibbon monkey leukemia fusogenic glycoprotein inserted into the viral genome in place of the ICP34.5 genes. The herpes simplex viruses of the invention may also comprise one or more heterologous genes. A heterologous gene refers to a gene to be introduced into the genome of a virus, in which that gene is not normally found in the genome of the virus or is a homolog of a gene expressed in the virus of a different species that has a nucleic acid sequence and may act through a different biochemical mechanism. Heterologous genes may encode one or more proteins, for example, a cytotoxin, an immunomodulatory protein (i.e., a protein that enhances or suppresses a host immune response to an antigen), a tumor antigen, a prodrug activator, a tumor suppressor, a prodrug-converting enzyme, proteins capable of inducing cell fusion, an antisense RNA molecule with respect to the TAP inhibitor, or a ribozyme. Examples of immunomodulatory proteins include, for example, cytokines.Cytokines include interleukins, such as IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-20; interferons α, β, and γ, tumor necrosis factor alpha (TNFα), CD40L, granulocyte-macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), and granulocyte-macrophage colony-stimulating factor (G-CSF), chemokines (such as neutrophil activating protein (NAP), macrophage chemoattractant activating factor (MCAF), RANTES, and macrophage inflammatory peptides MIP-1α and MIP-1β), complement components and their receptors, accessory molecules of the immune system (e.g., B7.1 and B7.2), adhesion molecules (e.g., ICAM-1, 2, and 3), and receptor molecules of adherence.Tumor antigens include human papillomavirus E6 and E7 antigens, EBV-derived proteins, mucins such as MUC1, melanoma tyrosinase, and MZ2-E. Prodrug activators include nitroreductase and cytochrome p450, tumor suppressors include p53, and enzymes that convert prodrugs include cytosine deaminase. Proteins capable of inducing cell fusion include gibbon leukemia fusogenic glycoprotein. TAP inhibitors include bovine herpesvirus (HBV) polypeptide UL49.5. Opposite-sense RNA molecules can be used to block the expression of a cellular or pathogenic mRNA. RNA molecules can be a ribozyme (e.g., a hammerhead or hairpin ribozyme) designed to repair defective cellular RNA or to destroy unwanted cellular or pathogen-encoded RNA. Also included is the insertion of multiple viral genes into the herpes simplex genome, such as the insertion of one or more copies of the gene that codes for the viral protein Us11. The eneolytic viruses described herein (e.g., talimogene laherparepvec) can be used to treat a wide variety of tumor types, including, but not limited to, melanoma, head and neck cancer, breast cancer (e.g., triple-negative breast cancer), colorectal cancer, hepatocellular carcinoma, gastroesophageal cancer (e.g., adenocarcinoma or squamous cell carcinoma), non-small cell lung cancer, and clear cell renal cell carcinoma. In one particular embodiment, the tumor type is melanoma. In various aspects, the liquid composition (e.g., reconstituted) comprises at least approximately 1 x 10⁵ plate-forming units / mL (PFU / mL). For illustrative purposes, the liquid composition (e.g., reconstituted) comprises at least approximately 2.0 x 10⁵ PFU / mL, at least approximately 3.0 x 10⁵ PFU / mL, at least approximately 4.0 x 10⁵ PFU / mL, at least approximately 5.0 x 10⁵ PFU / mL, at least approximately 6.0 x 10⁵ PFU / mL, at least approximately 7.0 x 10⁵ PFU / mL, at least approximately 8.0 x 10⁵ PFU / mL, or at least approximately 9.0 x 10⁵ PFU / mL. In certain aspects, the liquid composition (e.g., reconstituted) comprises at least approximately 1.0 x 10⁶UFP / mL to approximately 1.0 x 10⁸UFP / mL or 1.0 x 10⁶ plate-forming units / mL (UFP / mL) to approximately 1.0 x 10⁸UFP / mL, optionally approximately 1.1 x 10⁶UFP / mL, at least approximately 1.2 x 10⁶UFP / mL, at least approximately 1.3 x 10⁶UFP / mL, at least approximately 1.4 x 106. PFU / mL, at least about 1.5 x 106PFU / mL, at least about 1.6 x 106 PFU / mL, at least about 1.7 x 106PFU / mL, at least about 1.8 x 106 UFP / mL, at least approximately 1.9 x 106UFP / mL. In particular embodiments, the liquid composition (e.g., reconstituted) comprises approximately 1 x 106UFP / mL or 1 x 108UFP / mL. Power and stability Lyophilization is a process that removes water from samples. In general, lyophilization results in improved storage stability compared to storage in liquid form. However, because lyophilization involves freezing and dehydration (by sublimation), it is also a stressful process, particularly for biological agents such as enveloped viruses. Although lyophilization can improve long-term stability, the stress of the process can also inactivate some of the agent. RrQ / nn / Lznz / B / Yu significant of the agent of interest causing a significant loss of potency. A satisfactory formulation will not only provide adequate liquid stability and stability in the dry state, but will also minimize losses due to the freeze-drying process. Developing formulations that stabilize labile agents (such as enveloped viruses) simultaneously in both the liquid and lyophilized states is a well-known challenge, as the optimal compositions for each state are mutually exclusive and, consequently, generally not ideal for the other. However, it is important for a lyophilized product that a formulation adequately maintains the stability of the active agent in both the liquid and lyophilized states. This is because virtually all stages of a manufacturing process prior to lyophilization occur in the liquid state, and therefore the activity of the active ingredient must be preserved until the point of lyophilization.Similarly, after lyophilization, if the product needs to be reconstituted (for example, for use as a liquid), the stability of the liquids is important to ensure that potency is maintained for a duration appropriate for subsequent handling and storage. Furthermore, the lyophilization process itself can be destructive to biological agents, particularly enveloped viruses, which are sensitive to osmotic stress and the effects of cryoconcentration that occur during the freezing stage of lyophilization, as well as the effects of dehydration during the drying stages. Prior to this description, developing formulations that adequately stabilize a labile agent, such as an enveloped virus, in both the liquid and lyophilized states remained a significant challenge.Without intending to impose any particular theory, the liquid compositions described herein overcome these challenges. These compositions adequately stabilize a live attenuated virus in both the lyophilized and liquid states in several respects. In several cases, when the liquid composition is lyophilized or cryodried and subsequently reconstituted with water to produce a reconstituted product, the potency of the live attenuated virus in the reconstituted product is at least or approximately 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 90% of the potency of the live attenuated virus before lyophilizing the liquid composition. In some embodiments, the potency of the live attenuated virus in the reconstituted product is at least or approximately 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, or 50% of the potency of the live attenuated virus before lyophilizing the liquid composition. In other embodiments, the potency of the live attenuated virus in the reconstituted product is at least or approximately 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, or 40%.In some embodiments, the potency of the live attenuated virus in the reconstituted product is at least or approximately 35% of the potency of the live attenuated virus before lyophilization of the liquid composition. In several cases, when the liquid composition is lyophilized or cryodried and subsequently reconstituted with water to produce a reconstituted product, the potency of the live attenuated virus in the reconstituted product exhibits a loss of less than 1 logarithmic unit from the potency of the live attenuated virus in the reconstituted product. In some embodiments, the reconstituted product exhibits a loss of less than approximately 1 logarithmic unit, 0.9 logarithmic units, 0.8 logarithmic units, 0.7 logarithmic units, 0.6 logarithmic units, 0.5 logarithmic units, 0.4 logarithmic units, 0.3 logarithmic units, 0.2 logarithmic units or 0.1 log unit of the potency of the live attenuated virus in the reconstituted product. In specific embodiments, the reconstituted product exhibits a loss of less than approximately 0.6 log units, 0.5 log units, or 0.4 log units of the potency of the live attenuated virus in the reconstituted product. In specific embodiments, the reconstituted product exhibits a loss of less than approximately 0.6 log units, 0.5 log units, or 0.4 log units of the potency of the live attenuated virus in the reconstituted product. In another embodiment, the reconstituted product exhibits a loss of less than approximately 0.5 log units of the potency of the live attenuated virus in the reconstituted product. In some aspects, the liquid composition is lyophilized or cryodried and subsequently reconstituted with water to produce a reconstituted product; the potency of the live attenuated virus in the reconstituted product is at least or approximately 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 90% of the potency of the live attenuated virus before lyophilizing the liquid composition. In some embodiments, the liquid composition is lyophilized or cryodried and subsequently reconstituted with water to produce a reconstituted product; the potency of the live attenuated virus in the reconstituted product is at least or approximately 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49% or 50% of the potency of the live attenuated virus before lyophilizing the liquid composition.In other embodiments, the liquid composition is lyophilized or cryodried and subsequently reconstituted with water to produce a reconstituted product; the potency of the live attenuated virus in the reconstituted product is at least or approximately 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, or 40%. In some embodiments, when the liquid composition is lyophilized or cryodried and subsequently reconstituted with water to produce a reconstituted product, the potency of the live attenuated virus in the reconstituted product is at least or approximately 35% of the potency of the live attenuated virus before the liquid composition is lyophilized.In several cases, when the liquid composition is lyophilized or cryodried and subsequently reconstituted with water to produce a reconstituted product, the potency of the live attenuated virus in the reconstituted product exhibits a loss of less than 1 log unit. In some embodiments, the reconstituted product exhibits a loss. Rea / nn / Lznz / E / Yii of less than approximately 1 log unit, 0.9 log units, 0.8 log units, 0.7 log units, 0.6 log units, 0.5 log units, 0.4 log units, 0.3 log units, 0.2 log units, or 0.1 log units of the potency of the live attenuated virus in the reconstituted product. In specific embodiments, the reconstituted product exhibits a loss of less than approximately 0.6 log units, 0.5 log units, or 0.4 log units of the potency of the live attenuated virus in the reconstituted product. In specific embodiments, the reconstituted product exhibits a loss of less than approximately 0.6 log units, 0.5 log units, or 0.4 log units of the potency of the live attenuated virus in the reconstituted product. In another embodiment, the reconstituted product exhibits a loss of less than approximately 0.5 logarithmic units of the potency of the live attenuated virus in the reconstituted product. In many cases, when the liquid composition is freeze-dried or lyophilized, the resulting freeze-dried or lyophilized product is stable during storage or its shelf life. For example, the freeze-dried or lyophilized product can be stored long-term at temperatures of approximately -25°C to approximately 10°C, approximately -20°C to approximately 8°C, approximately -15°C to approximately 8°C, approximately -10°C to approximately 8°C, approximately -10°C to approximately 5°C, or approximately 2°C to approximately 8°C. In other embodiments, the freeze-dried or lyophilized product can be stored long-term at a temperature of approximately -25°C, -24°C, -23°C, -22°C, -21°C, -20°C, -19°C, -18°C, 17°C, -16°C, -15°C, -14°C, -13°C, -12°C, -11°C, -10°C, -9°C, -8°C, -7°C, -6°C, -5°C, -4°C, -3°C, -2°C, -1°C, 0°C, 1°C, 2°C, 3°C, 4°C, 5°C, 6°C, 7°C, 8°C, 9°C or 10°C.The freeze-dried or lyophilized product can be stored at these temperatures for at least or approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 months. In other embodiments, the freeze-dried or lyophilized product can be stored at these temperatures for at least or approximately 9–24 months, approximately 12–24 months, approximately 12–18 months, approximately 12–15 months, or approximately 10–15 months. Optionally, the freeze-dried or lyophilized product can be stored long-term at a temperature of approximately 2°C to approximately 8°C for at least 12, 15, 18, 21, or 24 months. Freeze-dried and cryo-dried products and powders The liquid compositions currently disclosed are suitable for dehydration, freeze-drying, or lyophilization. When these liquid compositions are dehydrated, freeze-dried, or lyophilized, the resulting dehydrated, freeze-dried, or lyophilized product exhibits remarkable stability during storage and a prolonged shelf life. Upon reconstitution, the product is characterized by minimal or reduced loss. Rea / nn / Lznz / E / Yii of the potency of live viruses. Accordingly, this disclosure provides a product produced by dehydration, freeze-drying, or lyophilization of any one of the currently disclosed liquid compositions. In some respects, the product is a powder. In other respects, the solid product may be described as a cake. Also, in connection with the foregoing, this disclosure provides a powder or cake produced by a method comprising the removal of water (dehydration, for example, by freeze-drying) from a composition comprising a live attenuated HSA virus (for example, rHSA), a non-lactose sugar, an alditol, a phosphate source, and a chloride source. Optionally, the composition is substantially free of lactose, gelatin, antibiotics, and amino acids. In some aspects, the composition is frozen, and the removal of water from the frozen composition is carried out under vacuum. Accordingly, by way of illustration, the method comprises freezing a liquid composition of this disclosure, removing water from the frozen composition under vacuum, and sublimating the ice from the frozen composition to a vapor state without passing through the liquid phase.The method may include additional steps such as sterilizing the liquid composition by passing it through a 0.22-micrometer bacterial retention filter and / or filling vials with the sterilized liquid composition. In various respects, the powder or cake is a lyophilized powder or a lyophilized cake. In some respects, the liquid composition comprises a live attenuated HSV-1 (e.g., talimogene laherparepvec), approximately 18 mg / mL to approximately 22 mg / mL of HSA (e.g., rHSA), approximately 3.4 mg / mL to approximately 4.2 mg / mL of sucrose, approximately 26 mg / mL to approximately 31.9 mg / mL of sorbitol, approximately 13 mg / mL to approximately 16 mg / mL of potassium phosphate, and approximately 5.1 mg / mL to approximately 6.3 mg / mL of sodium chloride.Accordingly, a powder or cake (e.g., a freeze-dried powder or a freeze-dried cake) produced by a method comprising removing water (e.g., dehydration, e.g., by freeze-drying) from a composition comprising an attenuated live HSV-1 (e.g., talimogene laherparepvec), approximately 18 mg / mL to approximately 22 mg / mL of HSA (e.g., rHSA), approximately 3.4 mg / mL to approximately 4.2 mg / mL of sucrose, approximately 26 mg / mL to approximately 31.9 mg / mL of sorbitol, approximately 13 mg / mL to approximately 16 mg / mL of potassium phosphate, and approximately 5.1 mg / mL to approximately 6.3 mg / mL of sodium chloride is further provided herein. Optionally, the composition is substantially free of lactose, gelatin, antibiotics, and amino acids.In some aspects, the composition is frozen to obtain a composition comprising ice before water removal, and optionally, the method further comprises placing the composition under vacuum after water removal. In certain aspects, the powder is stable in storage for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 months at a temperature below or about 8°C. In certain aspects, the powder is stored stably for at least 12, 15, 18, 21, or 24 months at a temperature below or about 82°C. A dehydrated product (e.g., a freeze-dried product, a cryo-dried product), which may be in the form of a powder or cake, comprising a live attenuated virus, is further provided herein. In illustrative embodiments, the product further comprises an HSA (e.g., rHSA), a sugar other than lactose, a sugar alcohol, a phosphate source, a chloride source, and optionally, where the composition is substantially free of lactose, gelatin, antibiotics, and free amino acids. In various aspects, the product (e.g., the powder or cake) comprises from approximately 10% to approximately 50% by weight of HSA (e.g., rHSA), for example, from approximately 15% to approximately 45% by weight, 20% to approximately 40% by weight, 25% to approximately 35% by weight, and 25% to approximately 30% by weight. In various aspects, the product comprises approximately 24.66% by weight to approximately 30.14% by weight of HSA (e.g., rHSA) or less than 30% by weight of HSA (e.g., rHSA), e.g., approximately 25%, approximately 26%, approximately 27%, approximately 28%, approximately 29% of HSA (e.g., rHSA). In illustrative cases, the product (e.g., powder or cake) comprises less than approximately 10% sugar, optionally, from approximately 2.5% by weight to approximately 7.5% by weight of sugar (e.g., sucrose), optionally, from approximately 4.68% by weight to approximately 5.72% by weight. In illustrative cases, the sugar is sucrose and is optionally present in an amount of approximately 2.5% by weight to approximately 7.5% by weight, optionally, from approximately 4.68% by weight to approximately 5.72% by weight (e.g., approximately 4.7% by weight, approximately 4.8% by weight, approximately 4.9% by weight, approximately 5.0% by weight, approximately 5.1% by weight, approximately 5.2% by weight, approximately 5.3% by weight, approximately 5.4% by weight, approximately 5.5% by weight, approximately 5.6% by weight, approximately 5.7% by weight). In illustrative cases, the product (e.g., powder or cake) comprises less than approximately 50% by weight of alditol (e.g., sorbitol). In some aspects, the product comprises less than approximately 45% by weight and optionally more than approximately 5% by weight, more than approximately 10% by weight, more than approximately 15% by weight, more than approximately 20% by weight, more than approximately 25% by weight, or more than approximately 30% by weight. In certain cases, alditol (e.g., sorbitol) is present in the product in an amount of approximately βρα / ηη / ίζηζ / E / γι. 35% by weight to approximately 45% by weight, for example, approximately 36% by weight, approximately 37% by weight, approximately 38% by weight, approximately 39% by weight, approximately 40% by weight, approximately 41% by weight, approximately 42% by weight, approximately 43% by weight, approximately 44% by weight, approximately 45% by weight. In illustrative cases, the product (for example, the powder or cake) comprises the phosphate source (for example, potassium phosphate) and an amount of less than approximately 50% by weight, optionally less than approximately 40% by weight, less than approximately 30% by weight, or less than approximately 25% by weight. In some aspects, the product comprises from approximately 15% by weight to approximately 25% by weight of phosphate source (e.g., potassium phosphate), optionally from approximately 17.87% by weight to approximately 21.85% by weight.In various aspects, the product comprises the chloride source (e.g., sodium chloride) in an amount of less than approximately 20% by weight or less than approximately 15% by weight. In some cases, the product comprises from approximately 5% to approximately 10% by weight of chloride source (e.g., sodium chloride), or optionally, from approximately 7.0% to approximately 8.6% by weight of sodium chloride. With respect to the currently disclosed powder, the quoted weight % refers to the number of grams of the indicated component relative to the sum of the grams of all powder components excluding the live virus, and is expressed as a percentage. For example, the weight % of rHSA = [(grams of rHSA) - (grams of rHSA + grams of sugar + grams of alditol + grams of phosphate source + grams of chloride source)]*100. In illustrative cases, after the addition of approximately 1 mL of water (e.g., approximately 0.9 mL, approximately 1.0 mL, approximately 1.1 mL, or approximately 1.2 mL), the powder constitutes a liquid composition comprising 80 mM to approximately 85 mM (e.g., approximately 80 mM, approximately 81 mM, approximately 82 mM, approximately 83 mM, approximately 84 mM, approximately 85 mM) potassium phosphate, approximately 95 mM to approximately 100 mM (e.g., approximately 95 mM, approximately 96 mM, approximately 97 mM, approximately 98 mM, approximately 99 mM, approximately 100 mM) sodium chloride, and approximately 2.5% (w / v) to approximately 3.0% (w / v) sodium chloride (e.g., approximately 2.5% (w / v) of potassium phosphate, approximately 95 mM to approximately 100 mM ... chloride, and approximately 2.5% (w / v) to approximately 3.0% (w / v) of sodium chloride (e.g., approximately 2.5% (w / v) of potassium phosphate, approximately 95 mM to approximately 100 mM of potassium phosphate, approximately 95 mM to approximately 100 mM of potassium phosphate, approximately 95 mM to approximately 100 mM of potassium 2.6% (w / v), of approximately 2.7% (w / v), of approximately 2.8% (w / v), of approximately 2.9% (w / v), of approximately 3.0% (w / v) sorbitol, from approximately 0.35% (w / v) to approximately 0.40% (w / v) (e.g., from approximately 0.35% (w / v), from approximately 0.36% (w / v), from approximately 0.37% (w / v), from approximately 0.38% (w / v), from approximately 0.39% (w / v), from approximately. Rea / nn / Lznz / E / Yii 0.40% (w / v) of sucrose, and approximately 1.95% (w / v) to approximately 2.05% (w / v) (e.g., approximately 1.95% (w / v), approximately 1.96% (w / v), approximately 1.97% (w / v), approximately 1.98% (w / v), approximately 1.99% (w / v), approximately 2.00% (w / v), approximately 2.01% (w / v), approximately 2.02% (w / v), approximately 2.03% (w / v), approximately 2.04% (w / v), approximately 2.05% (w / v)) of recombinant HSA. In other illustrative cases, sufficient water is added to reconstitute the powder to approximately 1 mL of volume. A liquid composition comprising water and the currently disclosed dehydrated product, powder, or cake is provided herein. In some aspects, the liquid composition comprises approximately 0.95 mL to approximately 1.5 mL of water, optionally approximately 1.0 mL of water. In some aspects, the liquid composition comprises at least or approximately 10⁶ FFU of live attenuated virus per mL of liquid composition, has a pH of approximately 7.4, and comprises approximately 80 mM to approximately 85 mM potassium phosphate, approximately 95 mM to approximately 100 mM sodium chloride, approximately 2.8% (w / v) to approximately 3.0% (w / v) sorbitol, approximately 0.36% (w / v) to approximately 0.40% (w / v) sucrose, and approximately 1.98% (w / v) to approximately 2.02% (w / v) recombinant HSA.In other respects, the liquid composition comprises at least or approximately 108PFU of live attenuated virus per mL of liquid composition, has a pH of approximately 7.4, and comprises approximately 80 mM to approximately 85 mM of potassium phosphate, approximately 95 mM to approximately 100 mM of sodium chloride, approximately 2.8% (w / v) to approximately 3.0% (w / v) of sorbitol, approximately 0.36% (w / v) to approximately 0.40% (w / v) of sucrose, and approximately 1.98% (w / v) to approximately 2.02% (w / v) of recombinant HSA. Preparation methods This disclosure also provides methods for preparing an oncolytic virus for administration to a human subject, comprising adding water to any one of the currently disclosed powders, optionally wherein approximately 1.0 mL to approximately 1.2 mL of water is added to the powder. Optionally, the prepared pharmaceutical product is reconstituted no more than approximately 24, 36, or 48 hours prior to administration to the human subject. Treatment methods A method for treating a subject with a tumor or cancer is also provided. In illustrative embodiments, the method comprises administering to the subject a liquid composition of the present disclosure. In various instances, the method comprises adding water to any one of the currently disclosed dehydrated products (for example, a freeze-dried product, a cryo-dried product), which may be in the form of a powder or a cake, to Rea / nn / Lznz / E / Yii to obtain a liquid composition and administer the liquid composition to the subject. In illustrative cases, approximately 0.9 mL to approximately 1.2 mL of water are added to the powder to obtain a liquid composition and the method comprises injecting the liquid composition into the human subject. The currently disclosed formulations can be used to treat various tumors and cancers. For example, a patient is treated for a solid tumor using the currently disclosed method. For example, the patient is treated for cancer or a tumor of the prostate, breast, lung, liver, bladder, kidney, cervix, or colon. In various cases, the cancer or tumor is renal cell carcinoma, endometrial cancer, cervical carcinoma, adenocarcinoma, melanoma, lymphoma, or glioma. In various cases, the patient has a sarcoma, such as soft tissue or bone sarcomas. The patient, in various cases, has head and neck cancer. In various cases, the patient has a cancer, neoplasm, or malignant tumor, such as leukemia, carcinoma, or sarcoma.Cancer, in some respects, includes breast, brain, cervical, colon, head and neck, liver, kidney, lung, non-small cell lung, melanoma, mesothelioma, ovarian, sarcoma, stomach, uterine, and medulloblastoma cancers. It also includes Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, neuroblastoma, ovarian cancer, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia, primary brain tumors, malignant pancreatic insulinoma, malignant carcinoid, bladder cancer, precancerous skin lesions, testicular cancer, lymphomas, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary tract cancer, neoplastic hypercalcemia, endometrial cancer, adrenal cortex cancer, endocrine and exocrine neoplasms of the pancreas, and prostate cancer. These cancers and tumors are treated according to the methods described in these disclosures. As used herein, the terms patient and subject are used interchangeably and mean a mammal, including, but not limited to, a human or non-human mammal, such as a bovine, equine, canine, ovine, or feline. Preferably, the patient is a human being. A method for destroying tumor cells is also provided in this document. In some respects, tumor cells are cells of an astrocytoma, oligodendroglioma, meningioma, neurofibroma, glioblastoma, ependymoma, schwannoma, neurofibrosarcoma, medulloblastoma, melanoma cells, pancreatic cancer cells, prostate carcinoma cells, breast cancer cells, lung cancer cells, colon cancer cells, hepatoma cells, mesothelioma, or squamous cell carcinoma. Combinations Compositions, powders, and lyophilized or cryodried products may be used in conjunction with other treatment modalities, including but not limited to radiation, chemotherapy, therapeutic proteins, and surgery. Cryodesiccated Rea / nn / Lznz / E / Yii can be administered before, simultaneously with, or after other treatment modalities. Therapeutic proteins include immune checkpoint inhibitors. As used herein, the term immune checkpoint inhibitor refers to molecules that reduce, inhibit, interfere with, or modulate, wholly or partially, one or more checkpoint proteins. Checkpoint proteins regulate the activation or function of T lymphocytes. Numerous checkpoint proteins are known, such as CTLA-4 and its ligands CD80 and CD86; and PD-1 with its ligands PD-L1 and PD-L2. These proteins are responsible for costimulatory or inhibitory interactions of T lymphocyte responses. Immune checkpoint proteins regulate and maintain self-tolerance and the duration and amplitude of physiological immune responses. Immune checkpoint inhibitors include antibodies or are derived from antibodies.Checkpoint inhibitors include inhibitors of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). CTLA-4 inhibitors include tremelimumab, ipilimumab (also known as 10D1, MDX-D010) and marketed as Yervoy™, and anti-CTLA-4 antibodies described in U.S. patent numbers 5,811,097; 5,855,887; 6,051,227; 6,207,157; ​​6,682,736; 6,984,720; and 7,605,238. Other immune checkpoint proteins include programmed cell death 1 (PD-1) and programmed cell death ligands 1 and 2 (PDL1 and PDDL2).Examples of molecules that inhibit PD1 and PD-L1 and PD-L2 include nivolumab (MDX 1106, BMS 936558, ONO 4538), a fully human IgG4 antibody that binds to and blocks PD-1 activation by its ligands PD-L1 and PD-L2; pembrolizumab (lambrolizumab, MK-3475 or SCH 900475) marketed as KeytrudaTM; MPDL3280A, a genomodified anti-PD-L1 antibody (atezolizumab); CT-011; and AMP-224. BMS-936559 (MDX-1105-01 and those described in United States patents numbers 7,488,802; 7,943,743; 8,008,449; 8,168,757; 8,217,149, and in PCT published patent applications with numbers: WO03042402, WO2008156712, W02010089411,. W02010036959, WO2011066342, WO2011159877, WO2011082400, and WO2011161699. Other immune checkpoint inhibitors include lymphocyte activation gene 3 (LAG-3) inhibitors, such as IMP321, a soluble Ig fusion protein, B7 inhibitors, such as the anti-B7-H3 antibody, MGA271. TIM3 (T-cell immunoglobulin domain and mucin domain 3) inhibitors are also included. Physicians may administer the currently disclosed compositions, powders, and lyophilized and cryodried products until a dosage is reached that achieves the desired effect. The compositions, powders, and lyophilized and cryodried products may therefore be administered as a single dose or as two or more doses (which may or may not contain the same amount of the desired molecule) over time, by direct injection or other suitable method of administration. The lyophilized and cryodried RrQ / nn / Lznz / B / Yu products described herein may be administered, for example, once or more than once, for example, at regular intervals over a period of time. In general, the compositions, powders, and lyophilized and cryodried products described herein may be administered until the patient demonstrates a medically relevant degree of improvement compared to the baseline values ​​of the selected indicator(s). In one embodiment, the compositions, powders, and freeze-dried and lyophilized products comprise talimogene laherparepvec administered by intratumoral injection into injectable cutaneous, subcutaneous, and lymph node tumors at a dose of up to 4.0 ml of 10⁶ plaque-forming units / ml (PFU / ml) on day 1 of week 1, followed by a dose of up to 4.0 ml of 10⁸ PFU / ml on day 1 of week 4 and every 2 weeks (± 3 days) thereafter. The recommended volume of talimogene laherparepvec to be injected into the one or more tumors depends on the size of the tumor or tumors. All reasonably injectable lesions (cutaneous, subcutaneous, and lymph node diseases that can be injected with or without ultrasound guidance) should be injected with the maximum available dosage volume on each individual dosing occasion.On each day of treatment, it is recommended to prioritize injections as follows: any new injectable tumors that have appeared since the last injection; by tumor size, starting with the largest tumor; any previously injectable tumors that are now injectable. The following examples are provided simply to illustrate the present invention and in no way to limit its scope. EXAMPLES EXAMPLE 1 This example describes compositions and products illustrative of this disclosure. A liquid composition was prepared comprising the components listed in Table 1 in the indicated quantities. Live virus (either 1x10⁶ FPU or 1x10⁸ FPU) was added to the mixture. TABLE 1 RrQ / nn / Lznz / B / Yu Component Quantity Quantity Talimogene laherparepvec (Amount of active virus after lyophilization and reconstitution) 1x106 PFU or 1x108 PFU / mL 1x106PFU 1x108 PFU / mL Potassium phosphate 14.5 (mg / mL) 83 mM Sodium chloride 5.7 (mg / mL) 98 mM Sorbitol 29.0 (mg / mL) 159 mM Sucrose 3.8 (mg / mL) 11 mM Recombinant human serum albumin 20.0 (mg / mL) 0.3 mM Water for injection (WFI) Enough to reconstitute to ~1 mL Enough to reconstitute to ~1 mL Osmolality 550 mOsm / kg 550 mOsm / kg pH 7.4 7.4 βρα / ηη / ίζηζ / Ε / γι The mixture was introduced into glass vials and placed on pre-cooled shelves of a cryodesiccator and dried according to the following parameters, which were developed to minimize power losses and obtain a solid cake with an acceptable residual moisture content and acceptable visual appearance. Following cryodesiccation, the resulting freeze-dried or lyophilized product was analyzed by plate assay to determine viral potency as the primary indicator of recovery performance and stability. In addition, the product was also evaluated based on cake appearance, protein content, particle content, and residual water content. EXAMPLE 2 This example describes a method for storing the freeze-dried or lyophilized product described in Example 1. The cryo-dried or lyophilized product described in Example 1 (comprising any one of 1 x 10⁶ or 1 x 10⁸ PFU / mL of virus) was stored at different temperatures of 8°C and below (e.g., 5°C, -20°C) for a variety of storage times (e.g., up to 60 weeks). Another cryo-dried or lyophilized product was manufactured essentially as described in Example 1, except that the amount of live virus was 1 x 10⁷ PFU / mL. Aliquots of this product were also stored at different temperatures of 8°C and below (e.g., 5°C and -20°C) for a variety of storage times (e.g., up to 60 weeks). After storage, an aliquot of each lyophilized sample was reconstituted with approximately 1.0–1.2 mL of water. The potency of the virus present in the reconstituted material was analyzed using a plate assay, a standard cell culture method in virology that uses permissive cells in culture to quantify the overall infectivity and replication capacity of the virus. Freeze-drying biologically active compounds frequently results in a significant loss of activity; therefore, one of the goals in developing a freeze-dried formulation is to minimize the degree of potency loss caused by freeze-drying. As shown in Table 2, the formulation results in a potency loss of approximately 60% (or 0.4 logw PFU / mL) for both viral concentrations of 1 x 10⁶ PFU / mL and 1 x 10⁸ PFU / mL, indicating that the extent of the loss is independent of the active ingredient concentration. This potency loss represents a significant improvement compared to the losses observed when traditional frozen formulations are freeze-dried, which can exhibit a loss of 1 logw PFU / mL or greater (equivalent to a 90% loss or more). Table 1: Summary of potency loss due to lyophilization βρα / ηη / ίζηζ / E / γι Expected concentration (UFP / mL) Loss of potency (%) due to lyophilization) 1x106 58 1x108 57 Table 3 contains potency data for the lyophilized virus intended to contain 1 x 10⁶ PFU / mL and stored at -20°C and 5°C for up to 60 weeks. Overall, there are no significant changes in the potency of the lyophilized virus over the 60 weeks at the indicated storage temperatures, indicating that the material has stabilized correctly. The potency deviations are within the variability of the method. Table 2: Lyophilized virus potency intended to contain 1x106UFP / mL stored at -20°C and 5°C Weeks Power (Logio UFP / mL) -20°C 5°C 0 5.9 5.9 9 6.1 5.5 30 5.9 5.7 60 6.0 5.8 Table 4 contains potency data for the lyophilized virus intended to contain 1 x 10⁸ PFU / mL and stored at 5°C for up to 13 weeks. Overall, there are no significant changes in the potency of the lyophilized virus over the 13 weeks at the indicated storage temperatures, indicating that the material has stabilized correctly. The potency deviations are within the variability of the method. Table 3: Lyophilized virus potency intended to contain 1x108UFP / mL stored at 5°C Rea / nn / Lznz / E / Yii Weeks Power (Logio UFP / mL) at 5C 0 8.0 4 8.1 9 8.0 13 7.9 The reconstituted material was also analyzed to determine pH and osmolality, with resulting values ​​of pH 7.4 and an osmolality of 550 mOsm / kg. The appearance of the product is an important attribute; a product that does not meet its specified appearance criteria could result in the rejection or return of the batch of virus in question. The formation of particulate matter, both during manufacturing and at later times (e.g., during storage), is a significant concern for all biological substances. Due to the formulation, the reconstituted material (containing 1 x 10⁶ PFU / mL of virus) is virtually free of any detectable particles and, as shown in Figures 1 and 2, also exhibits extremely low levels of subdividable particles. Similar results were obtained with material formulated to contain 1 x 10⁶ PFU / mL. EXAMPLES This example demonstrates improved activity recovery (virus infectivity) and subsequent storage stability of both liquid and lyophilized live virus formulations using different combinations of sugar and protein stabilizers compared to other similar known compositions. Lyophilization is a process that removes water from samples. In general, lyophilization results in improved storage stability compared to liquid storage. However, because lyophilization involves freezing and dehydration (by sublimation), it is also a stressful process, particularly for biological agents such as enveloped viruses. Although lyophilization can improve long-term stability, the stress of the process can also inactivate a significant portion of the agent of interest, causing a significant loss of potency. A successful formulation will not only provide adequate liquid and dry stability but will also minimize losses due to the lyophilization process. Developing formulations that stabilize labile agents (such as enveloped viruses) simultaneously in both liquid and lyophilized states is a well-known challenge, as the optimal compositions for each state are mutually exclusive and, consequently, generally not ideal for the other. However, for a lyophilized product, it is important that a formulation adequately maintain the stability of the active agent in both the liquid and lyophilized states, because virtually all manufacturing steps prior to lyophilization occur in the liquid state, and therefore the activity of the active ingredient must be preserved until the point of lyophilization.Similarly, after freeze-drying, if the product needs to be reconstituted (for example, for use as a liquid), liquid stability is important to ensure that potency is maintained for a duration appropriate for subsequent handling and storage. Furthermore, the freeze-drying process itself can be destructive to biological agents, particularly enveloped viruses, which are sensitive to osmotic stress and the effects of cryoconcentration that occur during the freezing stage of freeze-drying, as well as the effects of dehydration during the drying stages. To date, developing formulations that adequately stabilize a labile agent, such as an enveloped virus, in both the liquid and freeze-dried states remains a significant challenge. Sucrose phosphate glutamate (SPGA) and SPGA-based formulations of albumin are well-known formulations in the field of stabilizing live agents, such as viruses. See, for example, White et al., Vaccine 34(32): 3676-3683 (2016) and Yannarell et al., J Virol Methods 102(1-2): 15-25 (2002). Formulations This study compared a formulation of the present invention (F4) with two SPGA-based formulations (F1 and F2), as well as a third formulation (F3). Formulation F4 differed from the SPGA-based formulations (F1 and F2) in that, for example, F4 did not contain glutamate, had limited amounts of sucrose but higher amounts of phosphate, and contained a sugar alcohol. Human albumin was present in all four formulations to demonstrate that the observed effects were not due to this single component, but rather to the collective effect of all the components present in the formulations. To determine whether there were differences between serum-derived and recombinant-derived human albumins, formulation F1 was prepared with serum-derived human albumin (HSA) and formulation F2 with recombinant human albumin (rHA). Formulations F3 and F4 were also prepared with recombinant human albumin to allow for relative comparisons with F2.Each formulation contained the same amount of starting virus (talimogene). Rea / nn / Lznz / E / Yii laherparepvec). Table 5 describes the composition of the formulations under test (F1, F2 and F3) compared to a composition of the present invention (F4 which is also described in Table 1). Table 5 rpq jnn / Lznz / E / Yi Excipient F1 (SPGA+HSA) F2 (SPGA+rHA) F3 (P.rHA.S+rHA) F4 (Lyo form.+rHA) KPO4 11 mM 11 mM 1.2 mM 83 mM NaPO4 6.4 mM KCI 2.2 mM NaCl 110 mM 98 mM K-Glutamate 4.5 mM 4.5 mM Na-Glutamate 5.9 mM Sorbitol 2.9 % Sucrose 7.5 % 7.5 % 5.0 % 0.4 % Human albumin (serum) 1.0% Human albumin (recombinant) 1.0% 1.0% 1.0% The performance of the formulations described in Table 5 was evaluated by comparing the relative levels of viral infectivity over time, both in the liquid and lyophilized states at different temperatures. Liquid state stability of the formulations Each of the four formulations (F1, F2, F3, F4) was prepared with equal amounts of talimogene laherparepvec, and aliquots of each were stored at 5°C and 25°C and tested over time (for 9 weeks) using a plaque assay to evaluate the amount of preserved viral activity (Figure 3). Figure 3 shows the degradation rates relative to formulation F4. These were obtained by determining the degradation rate for each formulation and then normalizing the rate against the rate observed for formulation F4. As can be seen in Figure 3, at 5°C, formulations F1 and F2 degraded 1.2 and 1.3 times faster (worse) than F4, respectively, while formulation F3 performed slightly better than F4, degrading at a rate 0.9 times that of F4. At 25°C, a controlled temperature indicative of ambient temperature conditions, formulation F4 performed better than the other three formulations. In general, formulation F4 performed comparatively better than the other formulations. This is especially evident at 25°C, a particularly relevant temperature from a processing perspective. Stability of the formulations in the lyophilized state Formulations F1, F2, F3, and F4 were placed in vials and lyophilized. They were then tested over time using a plate assay to evaluate the amount of viral activity preserved, as described in the previous section for liquid-state stability of the formulations. After lyophilization, the samples were tested immediately after reconstitution to determine the amount of activity remaining after lyophilization, or they were stored at 5°C for 10 weeks to determine their storage stability performance. All four formulations were lyophilized together using a conservative lyophilization cycle, based on the lowest glass transition temperature of the formulations and the observation that all four formulations exhibit similar temperature-dependent profiles during lyophilization.Since each formulation was dried in an optimal and comparable manner, a direct comparison of stability and loss of activity due to lyophilization (or recovery of activity) can be made. Figure 4 shows a comparison of the stability of lyophilized talimogene laherparepvec in each of the formulations relative to formulation F4. As can be seen, F4 is significantly more stable than F1 and F2, which degrade at rates 12.1 and 8.2 times faster than F4, respectively. Interestingly, F3, which performed slightly better than F4 in the liquid state, degraded 3.5 times faster in the lyophilized state. Recovery of activity In addition to stability during storage, another critical parameter for a freeze-dried product is the amount of activity recovered after freeze-drying (which is also referred to by its inverse condition, loss of activity due to freeze-drying). Figure 5 shows the activity recovery amounts relative to formulation F4. Activity recovery was calculated by determining the virus titer for each formulation before and after lyophilization. The titer before lyophilization represents 100% activity; the titer determined after lyophilization was used to calculate the percentage recovered. The recoveries were then normalized to formulation F4 to show how each formulation performed relative to F4 (F4 is not shown as it is set at 0%). It can be observed that formulations F1 and F2 lost significantly more activity (viral titer), 31% and 38%, respectively, than F4. In addition, F3 lost 12% more activity than F4. Overall, these data indicate that F4 retained more activity than F1, F2, and F3. Conclusion In general, the data on liquid stability, freeze-dried stability, and activity recovery reveal significant performance differences between formulations F1, F2, F3, and F4. These data support the finding that F4 retained more activity after freeze-drying, was significantly more stable, and yielded [more activity]. Rea / nn / Lznz / E / Yii comparatively better, especially under the 25°C condition, in relation to formulations F1 to F3. All references, including publications, patent applications and patents, cited herein are incorporated herein by reference to the same extent as if each reference were individually or specifically indicated as incorporated by reference and cited in full herein. The use of the terms “a,” “an,” and “the,” and similar referents used in the context of the description (especially in the context of the following claims) should be construed as encompassing both the singular and the plural, unless otherwise indicated herein or clearly contradicted by the context. The expressions comprising, having, including, and containing should be construed as open-ended expressions (i.e., as expressions meaning including, but not exhaustively), unless otherwise indicated. The mention of value ranges herein is merely intended to serve as a shorthand method of referring individually to each independent value within the range and each valuation criterion, unless otherwise indicated herein, and each separate value and valuation criterion is incorporated into the descriptive report as if it were mentioned individually herein. All methods described herein may be carried out in any suitable order, unless otherwise stated herein or the context clearly indicates otherwise. The use of any and all examples or illustrative expressions (e.g., such as) herein is intended merely to further illuminate the description and does not limit the scope of the claimed description unless otherwise claimed. Nothing in the specification should be construed as indicating that any unclaimed element is essential to carrying out the description. Preferred embodiments of the description herein are described, including the best embodiment known to the inventors. Variations from these preferred embodiments may become apparent to those skilled in the art upon reading the foregoing description. The inventors expect that those skilled in the art will use such variations as appropriate and do not intend for the description to be practiced in a manner different from that specifically described herein. Accordingly, this description includes all modifications and equivalents of the subject matter mentioned in the appended claims to the extent permitted by applicable law. Furthermore, every combination of the elements described above in all possible variations thereof is included in the description, unless otherwise stated herein or the context clearly indicates otherwise. RrQ / nn / Lznz / E / Yi NOVELTY OF THE INVENTION Having described the present invention as above, it is considered novel and, therefore, the contents contained in the following are claimed as property:

Claims

1. A liquid composition comprising: a live attenuated virus; recombinant human serum albumin (rHSA); a sugar other than lactose; an alditol; a phosphate source; and a chloride source, wherein the composition is substantially free of lactose, gelatin, antibiotics, and amino acids.

2. The liquid composition of claim 1, comprising more than approximately 5 mg / mL and less than approximately 25 mg / mL of rHSA.

3. The liquid composition of claim 1 or 2, comprising more than approximately 1 mg / mL and less than approximately 25 mg / mL of rHSA.

4. The liquid composition of any one of claims 1 to 3, comprising more than approximately 15 mg / mL and less than approximately 25 mg / mL of rHSA. Rea / nn / Lznz / E / Yii 5. The liquid composition of any one of claims 1 to 4, comprising from approximately 17.5 mg / mL to approximately 22.5 mg / mL of rHSA, optionally, from approximately 20 mg / mL ± 2 mg / mL of rHSA.

6. The liquid composition of any one of the preceding claims, wherein the sugar is sucrose.

7. The liquid composition of approximately 15 mg / mL of sucrose.

8. The liquid composition of approximately 10 mg / mL of sucrose.

9. The liquid composition of approximately 5 mg / mL of sucrose.

10. The liquid composition of claim 6, 7, 8, 9, which comprises less than approximately 3.8 mg / mL ± 0.38 mg / mL of sucrose.

11. The liquid composition of any one of the preceding claims, wherein the alditol is sorbitol.

12. The liquid composition of claim 11, comprising more than approximately 10 mg / mL sorbitol and less than approximately 50 mg / mL sorbitol.

13. The liquid composition of claim 12, comprising less than approximately 45 mg / mL of sorbitol.

14. The liquid composition of claim 13, comprising less than approximately 40 mg / mL of sorbitol.

15. The liquid composition of claim 14, comprising less than approximately 35 mg / mL of sorbitol.

16. The liquid composition of claim 15, comprising from approximately 26 mg to approximately 32 mg / mL of sorbitol.

17. The liquid composition of any one of the preceding claims, wherein the phosphate source is potassium phosphate.

18. The liquid composition of claim 17, comprising more than approximately 5 mg / mL and less than approximately 45 mg / mL of potassium phosphate.

19. The liquid composition of claim 18, comprising less than approximately 40 mg / mL of potassium phosphate.

20. The liquid composition of claim 19, comprising less than approximately 30 mg / mL of potassium phosphate.

21. The liquid composition of claim 20, comprising less than approximately 20 mg / mL of potassium phosphate.

22. The liquid composition of claim 21, comprising from approximately 13.5 mg to approximately 16 mg / mL of potassium phosphate.

23. The liquid composition of any one of the preceding claims, wherein the chloride source is sodium chloride.

24. The liquid composition of claim 23, comprising more than approximately 1 mg / mL and less than approximately 20 mg / mL of sodium chloride.

25. The liquid composition of claim 24, comprising less than approximately 15 mg / mL of sodium chloride.

26. The liquid composition of claim 25, comprising less than approximately 10 mg / mL of sodium chloride.

27. The liquid composition of claim 26, comprising from approximately 3 mg to approximately 7 mg / mL of sodium chloride.

28. The liquid composition of any one of the preceding claims, consisting essentially of or comprising: the live attenuated virus, rHSA, sucrose, sorbitol, potassium phosphate, and sodium chloride.

29. The liquid composition of any one of the preceding claims having a pH of approximately 7.2 to approximately 7.

6.

30. The liquid composition of claim 29, having a pH of approximately 7.

4. βρα / ηη / ίζηζ / E / γι 31. The liquid composition of any one of the preceding claims, having an osmolality of less than approximately 700 mOsm / kg, optionally less than approximately 650 mOsm / kg.

32. The liquid composition of claim 31, having an osmolality of less than approximately 600 mOsm / kg, optionally from approximately 525 mOsm / kg to approximately 575 mOsm / kg.

33. The liquid composition of any one of the preceding claims, comprising no more than approximately 0.01 mM of any of lactose, gelatin, antibiotic, and free amino acids, optionally, no more than approximately 0.001 mM of any of lactose, gelatin, antibiotic, and free amino acids.

34. The liquid composition of any one of the preceding claims wherein the live attenuated virus is a herpes simplex virus (HSV), optionally a strain of herpes simplex virus 1 (HSV-1).

35. The liquid composition of claim 34 wherein the VHSI-1 strain is selected from the group consisting of strain JS1, strain 17+, strain F, and strain KOS.

36. The liquid composition of claim 34, wherein the herpes simplex virus is selected from the group consisting of talimogene laherparepvec, Seprehvir™, G207, OrienXOlO, NV1020, M032, ImmunoVEX and OncoVEXGALV / CD.

37. The liquid composition of claim 36, wherein the VHS is talimogene laherparepvec.

38. The liquid composition of any one of the preceding claims, wherein, when the liquid composition is lyophilized and then reconstituted with water to produce a reconstituted product, the potency of the live attenuated virus in the reconstituted product is at least or approximately 30% of the potency of the live attenuated virus before the liquid composition is lyophilized, optionally at least or approximately 35% of the potency of the live attenuated virus before the liquid composition is lyophilized.

39. The liquid composition of claim 38, wherein, when the liquid composition is lyophilized and then reconstituted with water to produce a reconstituted product, the potency of the live attenuated virus in the reconstituted product is at least or approximately 30% of the potency of the live attenuated virus before the liquid composition is lyophilized, optionally at least or approximately 40% of the potency of the live attenuated virus before the liquid composition is lyophilized.

40. A liquid composition comprising: an attenuated live HSV-1; from approximately 18 mg / mL to approximately 22 mg / mL of recombinant human serum albumin (rHSA); from approximately 3.4 mg / mL to approximately 4.2 mg / mL of sucrose; from approximately 26 mg / mL to approximately 31.9 mg / mL of sorbitol; from approximately 13 mg / mL to approximately 16 mg / mL of potassium phosphate; and from approximately 5.1 mg / mL to approximately 6.3 mg / mL of sodium chloride, wherein the composition is substantially free of lactose, gelatin, antibiotics, and amino acids.

41. A product produced by lyophilizing the liquid composition of any one of the preceding claims.

42. A powder produced by a method comprising removing water from a composition, said composition comprising: a live attenuated virus; recombinant human serum albumin (rHSA); a sugar other than lactose; an alditol; a phosphate source; and a chloride source, wherein the composition is substantially free of lactose, gelatin, antibiotics, and amino acids.

43. A powder produced by a method comprising removing water from a composition, said composition comprising: an attenuated live HSV-1; from approximately 18 mg / mL to approximately 22 mg / mL of recombinant human serum albumin (rHSA); from approximately 3.4 mg / mL to approximately 4.2 mg / mL of sucrose; from approximately 26 mg / mL to approximately 31.9 mg / mL of sorbitol; from approximately 13 mg / mL to approximately 16 mg / mL of potassium phosphate; and from approximately 5.1 mg / mL to approximately 6.3 mg / mL of sodium chloride, wherein the composition is substantially free of lactose, gelatin, antibiotics, and amino acids.

44. The powder of claim 42 or 43, wherein the composition is frozen to obtain a composition comprising ice before removing the water.

45. The powder of claim 44, wherein the method further comprises placing the composition under vacuum at controlled temperatures and pressures to remove water.

46. ​​The powder of any one of claims 42 to 45, wherein the method is lyophilization. Rea / nn / Lznz / E / Yii 47. The powder of any one of claims 42-46, comprising less than approximately 3% w / w of water.

48. The powder of any one of claims 42-47, which is stable during storage for at least or approximately 1 month, 2 months, or 3 months at a temperature below or approximately 8 2C.

49. A liquid composition comprising water and the product of claim 41 or the dry powder of any one of claims 42-48.

50. The liquid composition of claim 49, comprising from approximately 0.95 mL to approximately 1.5 mL of water.

51. The liquid composition of claim 50, comprising approximately 1.0 mL of water.

52. The liquid composition of any one of claims 49-51, comprising at least or approximately 1x106 or 1x108 FPU of live attenuated virus per mL of liquid composition.

53. The liquid composition of any one of claims 49-52, having a pH of approximately 7.

4.

54. A powder comprising a live attenuated virus, recombinant human serum albumin (rHSA), a sugar other than lactose, an alditol, a phosphate source, a chloride source, wherein the composition is substantially free of lactose, gelatin, antibiotic, and free amino acids.

55. The powder of claim 54, comprising from 24.66% by weight to approximately 30.14% by weight of rHSA.

56. The powder of claim 54 or 55, wherein the sugar is sucrose.

57. The powder of claim 56, comprising from approximately 2.5% by weight to approximately 7.5% by weight of sucrose, optionally from approximately 4.68% by weight to approximately 5.72% by weight of sucrose.

58. The powder of any one of claims 54-57, wherein the alditol is sorbitol.

59. The powder of claim 58, comprising from approximately 25% by weight to approximately 33% by weight of sorbitol, optionally from approximately 35.76% by weight to approximately 43.7% by weight.

60. The powder of any one of claims 54-59, wherein the phosphate source is potassium phosphate.

61. The powder of claim 60, comprising from approximately 15% by weight to approximately 25% by weight of potassium phosphate, optionally from approximately 17.87% by weight to approximately 21.85% by weight. Rea / nn / Lznz / E / Yii 62. The powder of any one of claims 54-61, wherein the chloride source is sodium chloride.

63. The powder of claim 61, comprising from approximately 5% by weight to approximately 10% by weight of sodium chloride, optionally from approximately 7.0% by weight to approximately 8.6% by weight of sodium chloride.

64. The powder of any one of claims 54-63 which, upon the addition of approximately 1 mL of water, produces a liquid composition comprising approximately 80 mM to approximately 85 mM of potassium phosphate, approximately 95 mM to approximately 100 mM of sodium chloride, approximately 2.8% (w / v) to approximately 3.0% (w / v) of sorbitol, approximately 0.36% (w / v) to approximately 0.40% (w / v) of sucrose, and approximately 1.98% (w / v) to approximately 2.02% (w / v) of recombinant HSA.

65. A method for preparing an oncolytic virus for administration to a human subject, comprising adding water to the powder of any one of claims 54-64, optionally wherein from approximately 1.0 mL to approximately 1.2 mL of water is added to the powder.

66. A method for treating melanoma in a human subject, comprising adding water to the powder of any one of claims 54-64, optionally wherein approximately 1.0 mL to approximately 1.2 mL of water is added to the powder to obtain a liquid composition and injecting the liquid composition into the human subject.